U.K. biotech, U.S.-China research, Insmed — a BioCentury podcast

Amid pharma exodus, Tallon focusing MHRA on U.K.’s strengths

The announcement that Merck & Co. Inc. (NYSE:MRK) was moving its R&D out of the U.K. highlights concerns about the country’s life sciences policies. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the life sciences ecosystem in the U.K., including MHRA CEO Lawrence Tallon’s plans to create a world-class regulatory environment. They also discuss a bill passed by the U.S. House of Representatives that would end most U.S.-China academic research collaborations, and the recent success of 40-year-old biotech Insmed Inc. (NASDAQ:INSM).